Doctors and researchers have long said that stem cell therapy has the potential to change the face of human disease. But what if stem cells could be used to reverse the aging process as well?

Plastic surgeons say they can use stem cells to make women look years younger without the pain of an invasive surgery.

"I lost weight, loss of volume in face, I looked gaunt and I said, so I said, 'okay what do we do to fix this?'" said Sarah, a patient.

The fix for this was a stem-cell face lift. Dr. Steve Szczerba of Chicago Aesthetic Surgery Institute recommended that Sarah undergo a procedure, where he'd use her own adult stem cells to turn back the clock.

"A stem cell facelift is rejuvenating the face using grafted fat. Grafted fat has stem cells in it," Dr. Szczerba explains.

Grafted fat is transferred fat. Dr. Szczerba typically gets it from the patient's abdomen or inner thigh during liposuction.

"During that process of liposuction, we save the fat and take the fat and prepare it for grafting by removing the fluid. And the stem cells along with other grafted fat cells are injected into the face," says Dr. Szczerba.

He says it's not simply a fat transfer. Dr. Szcerba believes the stem cells, which are specialized cells that self renew, are actually working to make collagen and rejuvenate the skin.

"You can actually see the surface of the skin change," says the doctor. "Similar to that a chemical peel or a laser peel accomplishes in order to see change in your cheek area."

Click for more from My Fox Chicago.

Read the original post:
Stem cell face lift: Does it work?

Recommendation and review posted by simmons

AdvaMedDx: The Role of Advanced Diagnostics in Cancer Care - Cesar Garcia, President CEO, IRIS
Speaker: Cesar Garcia, President CEO, IRIS On September 20th, 2012, AdvaMedDx invited diagnostic manufacturers, the cancer research community, and a patient advocate to Capitol Hill briefing in Washington, DC to educate attendees on recent advances in cancer diagnostics that are improving the treatment and management of patients with cancer. Held in conjunction with the House Medical Technology Caucus, this briefing will explore how advanced diagnostics are delivering on the promise of personalized medicine. Leading medical technology manufacturers are developing new, state-of-the-art diagnostic tests to help physicians and patients make the most informed treatment decisions possible. These tests provide critical information that allow health care providers to detect and diagnose disease earlier, target treatments to the individual patient, utilize more preventative and less invasive treatment options, and manage diseases such as cancer more effectively. Innovation in molecular diagnostic tests hold great promise for identifying small genetic differences that can often impact diagnosis, prognosis, drug selection, and outcomes for cancer patients. Molecular diagnostic tests can be used to identify a particular existing disease or condition, identify a patient #39;s likelihood of recurrence, and identify genetic variability to allow for more accurate and targeted treatment selection tailored to individual needs. These advances in diagnostics are helping to improve patient ...From:AdvaMedDxViews:4 1ratingsTime:21:12More inNonprofits Activism

See original here:
AdvaMedDx: The Role of Advanced Diagnostics in Cancer Care - Cesar Garcia, President

Recommendation and review posted by sam

In a major step toward an era of personalized medicine, researchers reported Wednesday that they have sequenced the complete DNA material of more than 1,000 people from 14 population groups in Europe, Africa, East Asia and the Americas.

The report from the $120 million 1000 Genomes Project involved 700 scientists from laboratories in the U.S., Canada, China, Japan, Nigeria and Kenya, among others. Their results, published in Nature, offer the closest look yet at the differences in humankind's biological instruction set, documenting how myriad rare mutations may underpin many diseases and set the people of one locale apart from another in ways that shape their health.

All told, the scientists identified 38 million variations in the chemical letters of DNA that make up each of the average person's 23,000 or so genes and the DNA regions that control themabout 98 percent of all the estimated human variation in the world.

"We are getting to the point where an individual genome sequence can be a useful part of diagnosis," said statistical geneticist Gilean McVean at Oxford University in England, who led the effort. "If there is a variation that is present in just one in 100 people, we have found it,"

The immense compendium of genetic codea catalog of human variation equal to 16 million file cabinets of data, or 30,000 DVDsis meant to serve as a standard reference against which doctors could one day compare a patient's genome profile, even during a routine checkup.

Far from complete, the data already are straining the computer capacity of most laboratories to store and analyze. Moreover, the researchers expect to add genetic data from 1,500 more people within a few months. Earlier this year, Amazon.com Inc. volunteered to store the vast database in its cloud services, from which it could be freely accessed by anyone.

Generally, all humans share about 99 percent of the DNA code that shapes development, health, personality and other traits. But the common genetic variations that most people share account for only a fraction of the risk of inherited disease.

Click for more from The Wall Street Journal.

Read the original here:
1000 Genomes Project moves researchers closer to personalized medicine

Recommendation and review posted by sam

Benny - Our Paralyzed Dog Gives Us Hope
Benny suffered a spinal cord injury in May of 2012. This video archives the progress through the next 6 months.From:John KellyViews:1 0ratingsTime:09:27More inPets Animals

Link:
Benny - Our Paralyzed Dog Gives Us Hope - Video

Recommendation and review posted by sam

Disability Video
I made this video for newly disabled paraplegics who may have questions about their disability. Spinal Cord Injury Model System Informational Network http://www.uab.edu Feel free to email me at AshleyKitchings17@gmail.comFrom:Ashley KitchingsViews:2 3ratingsTime:12:45More inEducation

See the article here:
Disability Video - Video

Recommendation and review posted by sam

My spinal cord injury story (intro)
This wasn #39;t as short as I would have hoped I realize I say a lot of silly things in here but I hope that this video will help someone like previous YouTube videos helped me. My blog: http://www.sabrinadellinger.blogspot.com Twitter: @heysabrina_ Instagram: @heysabrina Email: sabrinatakespictures@gmail.comFrom:sabrina dellingerViews:71 5ratingsTime:14:48More inPeople Blogs

View original post here:
My spinal cord injury story (intro) - Video

Recommendation and review posted by sam

Sexual health after Spinal Cord Injury
From:cpaalbertaViews:0 0ratingsTime:09:24More inNonprofits Activism

Read more from the original source:
Sexual health after Spinal Cord Injury - Video

Recommendation and review posted by sam

November 2, 2012 Lindenwood's Thomas recovering from spinal injury

Anonymous The Joplin Globe The Joplin Globe Fri Nov 02, 2012, 12:17 AM CDT

Lindenwood defensive back Sterling Thomas remains hospitalized after suffering a severe spinal cord injury in Saturdays game against Missouri Southern.

According to a school press release, Thomas is on track with his recovery, and his parents said being in such good physical condition has helped him.

Thomas, from Tulsa, was injured midway through the fourth quarter when his helmet hit the leg of Missouri Southern receiver Landon Zerkel.

I dont know that it was an unusual play, Missouri Southern coach Daryl Daye said. You see those hits all the time. I guess the unusual part was that Landon never saw him coming, and (Thomas) kind of gets funneled back into make the play. From what I saw, his helmet was low and as a result of Landon not being able to avoid him, (Thomas) kind of got pushed into him to cause the contact.

It was a vicious hit, and Landon is still bruised up from it, the right side of his leg. Its tragic that it turned out for (Thomas) that way.

The Lindenwood team has dedicated the final two games of their season to Thomas. The Lions play Saturday afternoon at Pittsburg State.

Thomas teammates will sell bracelets that say S.T. #27 LU Soldier to assist with the familys expenses. Persons wanting to make a contribution to the Sterling Thomas Fund can contact Jane Baum, Lindenwood athletics development director, at 636-949-4427 or email her at jbaum@lindenwood.edu.

Visit link:
Lindenwood's Thomas recovering from spinal injury

Recommendation and review posted by sam

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today announced the appointment of Francois Binette, PhD, as OrthoCytes Vice President of Research and Business Development. Dr. Binettes primary focus will be to develop and partner near- and long-term product opportunities in regenerative medicine with an emphasis on orthopedic diseases and injuries. OrthoCyte is a wholly owned subsidiary of BioTime, Inc. that develops cellular therapeutics for orthopedic repair, diseases, and injuries.

I am impressed by the robust nature of the novel and diverse progenitors of skeletal tissues that BioTime has isolated using its ACTCellerateTM technology, said Dr. Binette. The ability to generate scalable and precisely identified types of cartilage, bone, and tendon, combined with the HyStem technology for tissue engineering, gives us a remarkable platform for manufacturing an array of novel products to address some of the largest and fastest growing needs in the orthopedic space. I look forward to building on the science and technology developed at OrthoCyte to aggressively develop the companys product pipeline and pursue partnering opportunities.

Francois brings tremendous expertise in regenerative medicine, cell therapy, biologics, biomaterials, and combination medical devices. He also has significant business experience in partnering and collaboration with both start-up and large life science companies, said Michael D. West, PhD, BioTimes Chief Executive Officer. We welcome Francois to the OrthoCyte team and look forward to working together with him in developing commercial product opportunities for the orthopedic repair market.

Dr. Binette most recently was the founder of Rediens Inc., a Bay Area start-up company focused on chronic back pain therapies. Prior to establishing Rediens, he wasDirector of BiologicsR&D for the Spinal & Biologics business unit of Medtronic, Inc., and he also served in a variety of positions with Johnson & Johnson, where he focused on regenerative medicine therapies for various orthopedic indications, including cartilage injuries and back pain. Dr. Binette began his corporate career at Genzyme Tissue Repair, where he helped pioneer Carticel, the first FDA Biologic License Application-approved cell therapy product. Dr. Binette received his PhD in Biochemistry at Laval University in Qubec and was a postdoctoral research fellow at the LaJolla Cancer Research Foundation of the Sanford-Burnham Medical Research Institute and at MGH/Harvard Medical School. He is currently a fellow with the International Cartilage Repair Society.

About OrthoCyte Corporation

OrthoCyte Corporation (OrthoCyte), http://www.orthocyte.com, a subsidiary of BioTime, Inc., is a biotechnology company developing cell-based therapies for orthopedic disease. The company's lead product is OTX-CP07, monoclonal human embryonic progenitor cell lines for the repair of osteoarthritis. In addition, OrthoCyte has proprietary human embryonic stem cell-derived progenitors to skeletal muscle, tendon, and bone, all of which are in the preclinical phase of development.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

See original here:
BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President

Recommendation and review posted by sam

NEW YORK, Nov. 1, 2012 (GLOBE NEWSWIRE) -- The Stem for Life Foundation, NeoStem, Inc. (NYSE MKT:NBS), The Pontifical Council for Culture, and STOQ International today announced that they will host The Second International Vatican Adult Stem Cell Conference: Regenerative Medicine -- A Fundamental Shift in Science & Culture, from within The Vatican, April 11-13, 2013.

This event is part of a five-year collaboration between The Stem for Life Foundation, a not-for-profit organization devoted to raising global awareness of the therapeutic potential of adult stem cells, NeoStem, an emerging leader in the fast growing cell therapy industry, The Vatican's Pontifical Council for Culture and its foundation, called STOQ International (Science, Theology and the Ontological Quest).

With renowned journalists serving as moderators -- Meredith Vieira from NBC News, Bill Hemmer from The Fox News Channel, Peggy Noonan of The Wall Street Journal and Dr. Max Gomez from WCBS-TV -- The Second International Vatican Adult Stem Cell Conference will feature leading adult stem cell scientists and clinicians, thought leaders of faith, ethics and culture, business leaders as well as Ministers of Health, Ambassadors to The Holy See and regulatory officials from around the world. During the event, adult stem cell scientists and clinicians will present an array of medical advancements and ongoing research occurring throughout the world, including the ability to grow replacements for damaged and diseased organs; restoring heart function after heart attack; growing new skin for burn victims; rebalancing our own immune systems, pushing back a rising tide of chronic disease; advancements in cancer therapy; preventing organ rejection and addressing a range of other conditions and trauma, such as MS, traumatic brain injuries and cardiovascular disease via adult stem cell therapies. Throughout the event, patients will share their own stories of the unique, powerful treatments that have helped address their disease and reduce suffering.

"Regenerative medicine is poised to revolutionize disease management by finding new ways to boost the body's ability to heal itself. Whereas today treatment for many diseases is a matter of managing symptoms, regenerative medicine seeks to reverse the course of the disease by targeting its cause and repairing diseased or defective tissues or organs," said Dr. Robin Smith, President of The Stem for Life Foundation. "Not only will our conference educate people of all ages, religions and cultures on the potential of adult stem cells to treat chronic disease as part of this next great frontier, but we will generate a truly international dialogue on regenerative medicine, one that explores the interconnections between scientific breakthroughs, faith, culture and ethics."

The goals of the 2013 Second International Vatican Adult Stem Cell Conference are to:

"The developments within regenerative medicine are of great interest," said Msgr. Tomasz Trafny. "They show how science changes, causing paradigm shifts through interdisciplinary research. Cellular biology is a good example of such changes. These dynamics also cause deep cultural transformations on different levels, from health care to economy, from new technologies to legal issues. Thus, topics that apparently seem to be circumscribed only to strictly scientific discussions or theoretical ones, in fact modify our understanding of social dynamics, relationships and, in the ultimate analysis, our understanding of the human being. Today we acknowledge that insights from natural sciences play a crucial role in our society, having consequences for anthropology, philosophy and even theology. It is our mission and our duty to explore the above dynamics, to offer the best tools for pastoral care, and to encourage understanding of changing culture."

In June, The Pontifical Council for Culture and The Stem for Life Foundation presented the first copy of their forthcoming book, The Healing Cell: How The Greatest Revolution in Medical History is Changing Your Life, to The Holy Father, Pope Benedict XVI. The book is the result of a unique collaboration between the two organizations, and will be available in 2013. It includes a special address by His Holiness Benedict XVI, urging increased support and awareness for advancements in adult stem cell research in order to alleviate human suffering. To reserve a copy of the book, go to:http://www.stemforlife.org/healingcell

To learn more about The Second International Vatican Adult Stem Cell Conference please visit http://www.adultstemcellconference.org.

About The Pontifical Council for Culture

The Pontifical Council for Culture is that Dicastery of the Roman Curia which assists the Pope in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the saving message of the Gospel and cultures, in the study of the weighty phenomena of the rift between the Gospel and cultures; indifference in matters of religion; unbelief. It is also concerned with relationships between the Church and the Holy See and the world of culture; in particular it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel, and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty. http://www.cultura.va

Link:
The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Announce 'The ...

Recommendation and review posted by sam

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Companys three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition, commented Gary Rabin, ACTs chairman and CEO. We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardts Macular Dystrophy.

ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardts Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the studys primary endpoint.

This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs, commented Robert Lanza, M.D., ACTs chief scientific officer. We look forward to treating these two patients and moving on to the third cohort in good time.

Further information about patient eligibility for ACTs SMD studies in the U.S. and E.U. as well as its dry AMD study in the U.S. are available atwww.clinicaltrials.gov,with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Visit link:
ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for ...

Recommendation and review posted by sam

HOLLISTON, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and nine months ended September 30, 2012.

Third Quarter Reported Results

Revenues for the three months ended September 30, 2012 were $26.1 million, a decrease of $0.3 million, or 1.0% compared to revenues of $26.4 million for the three months ended September 30, 2011. Currency exchange rates had a negative 1.4% effect on revenues in the third quarter of 2012 compared with the third quarter of 2011. Our acquisition of AHN Biotechnologie GmbH ("AHN") in February 2012 had a positive 1.6% effect on revenues. Excluding the effects of currency changes and acquisitions, our third quarter revenues decreased 1.2% from the same period last year.

Net (loss) income, as measured under U.S. generally accepted accounting principles ("GAAP"), was a $133,000 loss, or $0.00 per diluted share for the three months ended September 30, 2012 compared to a $28,000 income, or $0.00 per diluted share, for the same period in 2011. The unfavorable year-to-year quarterly GAAP earnings comparison was primarily due to increased spending of $0.7 million (pre-tax) in our development-stage Regenerative Medicine Device ("RMD") business.

On a non-GAAP adjusted basis, earnings per share for our core Life Science Research Tools ("LSRT") business for the three months ended September 30, 2012 was $0.08 per diluted share, compared with $0.07 per diluted share for the same period in 2011. Non-GAAP adjusted earnings per share for our RMD business for the third quarter of 2012 was a loss of $0.04 per diluted share, compared with a loss of $0.02 per diluted share for the third quarter of 2011, and reflected greater activities in developing this initiative. Our total non-GAAP adjusted earnings per share, reflecting LSRT and RMD combined, was $0.04 per diluted share for the third quarter of 2012 compared with $0.05 per diluted share for the third quarter of 2011.

Year to Date Reported Results

Revenues for the nine months ended September 30, 2012 were $82.9 million, an increase of $3.1 million, or 3.9% compared to revenues of $79.8 million for the nine months ended September 30, 2011. Currency exchange rates had a negative 1.5% effect on revenues for the nine months ended September 30, 2012, compared with the same period in the previous year. Our acquisitions of CMA Microdialysis AB ("CMA") in July 2011 and AHN in February 2012 had a positive 3.7% effect on revenues. Excluding the effects of currency changes and acquisitions, our organic revenue growth for the nine months ended September 30, 2012 was 1.7% over the same period in the previous year.

Net income, as measured under GAAP, was $1.2 million, or $0.04 per diluted share for the nine months ended September 30, 2012 compared to $3.1 million, or $0.10 per diluted share, for the same period in 2011. The unfavorable year-to-year quarterly GAAP earnings comparison was primarily due to increased activity and spending in our development-stage RMD business.

On a non-GAAP adjusted basis, earnings per share for our core LSRT business for the nine months ended September 30, 2012 was $0.28 per diluted share, compared with $0.25 per diluted share for the same period in 2011. Non-GAAP adjusted earnings per share for our RMD business for the nine months ended September 30, 2012 was a loss of $0.11 per diluted share, compared with a loss of $0.05 per diluted share for the same period in 2011, and reflected greater activities in developing this initiative. Our total non-GAAP adjusted earnings per share, reflecting LSRT and RMD combined, were $0.17 per diluted share for nine months ended September 30, 2012 compared with $0.20 per diluted share for the same period in 2011.

Commenting on the Company's performance, Chane Graziano, CEO, stated, "In the month of September, we saw a decrease in demand for our products primarily in the university/government research market. It is apparent the researchers were conserving their current budgets due to the uncertainty of the level of future funding in this political/economic environment. This had an impact on our third quarter performance."

See the article here:
HBIO Reports Third Quarter 2012 Results

Recommendation and review posted by sam

Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional?
Sunjay Kaushal USA More videos from the AHC 2011 conference are available here: river-valley.tvFrom:rivervalleytvViews:10 0ratingsTime:20:40More inScience Technology

See the original post here:
Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? - Video

Recommendation and review posted by Bethany Smith

Building a Self-Asembled Biobot using cardiac stem cells
Self-Assembly of micro scale Biobots using cardiac stem cells and MEMs structures. This technology was developed by Carlo Montemagno, currently Dean of the College of Engineering and Applied Science at the University of Cincinnati and his student Jianshong XiFrom:Carlo MontemagnoViews:99 1ratingsTime:01:07More inScience Technology

Here is the original post:
Building a Self-Asembled Biobot using cardiac stem cells - Video

Recommendation and review posted by Bethany Smith

BCVS 2012 - SCIPIO--Cell Therapy and Ischemic Cardiomyopathy
Roberto Bolli, MD and Jianyi Zhang, MD, PhD discuss the Use of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: The SCIPIO TrialFrom:AHAScienceNewsViews:170 1ratingsTime:08:10More inScience Technology

See the original post here:
BCVS 2012 - SCIPIO--Cell Therapy and Ischemic Cardiomyopathy - Video

Recommendation and review posted by Bethany Smith

University of Maryland Study Suggests Neonatal Cardiac Stem Cells May Help Restore Heart Function
Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells. Among their findings: cardiac stem cells (CSCs) from newborns have a three-fold ability to restore heart function to nearly normal levels compared with adult CSCs. Further, in pre-clinical models of heart attack, hearts treated with neonatal stem cells pumped stronger than those given adult cells. The study is published in the September 11, 2012, issue of Circulation. n this video the study #39;s senior author, Dr. Sunjay Kaushal, MD, Ph.D., director of pediatric cardiac surgery at the University of Maryland Medical Center, discusses the findings in more detail. Related Links: Maryland Heart Center http://www.umm.edu Children #39;s Heart Program http://www.umm.edu A Mission to Ecuador for Pediatric Heart Surgeon medcenterblog.org Your Health: Congenital Heart Disease http://www.umm.eduFrom:UMMCVideosViews:89 4ratingsTime:05:44More inScience Technology

Read the rest here:
University of Maryland Study Suggests Neonatal Cardiac Stem Cells May Help Restore Heart Function - Video

Recommendation and review posted by Bethany Smith

Critical Limb Trials Update
Lower limb amputation is a reality for thousands of people every year in South Carolina. Roper St. Francis Healthcare is leading the way in a clinical trial utilizing bone marrow stem cells to save limbs.From:RoperStFrancisViews:24 0ratingsTime:01:31More inScience Technology

See the article here:
Critical Limb Trials Update - Video

Recommendation and review posted by Bethany Smith

Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury || Stem Cell Treatments (Part 2 of 5)
Case studies of spinal cord injury patients treated with CD34+ and mesenchymal stem cells harvested from human umbilical cord Wharton #39;s jelly and cord blood, animal studies using mesenchymal stem cells, immunosuppression requirements in allogeneic stem cell treatments, intrathecal and intravenous administration of autologous bone marrow stem cells in spinal cord injury patients, and the role adult stem cell trophic factors in tissue regeneration.From:cellmedicineViews:623 5ratingsTime:12:57More inScience Technology

Continue reading here:
Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury || Stem Cell Treatments (Part 2 of 5) - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy for Critical Limb Ischemia - YouTube.flv
Dr. Michael Murphy discusses a previous trial using bone marrow stem cells, a clinical trial based upon research sponsored by Cryptic Masons Medical Research Foundation and ICVBM.From:CMMRF2012Views:69 1ratingsTime:01:39More inPeople Blogs

Read more here:
Stem Cell Therapy for Critical Limb Ischemia - YouTube.flv - Video

Recommendation and review posted by Bethany Smith

Dr.Mohamad Ghoneim
Dr.Mohamed Ahmed Ghoneim, MD (MD Hon.), Emeritus: Professor of Urology Mansoura University, Mansoura, Egypt. Dr.Ghoneim talks at the 2nd GCCTX11 Congress in Riyadh, Saudi Arabia,on October 4th 2011 about "Transplantation of Insulin producing cells derived from human Bone Marrow Stem Cells did Control."From:saudiorgantransplantViews:80 0ratingsTime:29:51More inScience Technology

Read the original here:
Dr.Mohamad Ghoneim - Video

Recommendation and review posted by Bethany Smith

Science Talk: Myelodysplastic Syndromes (MDS) Linked to Abnormal Stem Cells
http://www.einstein.yu.edu - July 2, 2012 - Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS). The findings published online July 2 in the journal Blood. See accompanying release http://www.einstein.yu.eduFrom:EinsteinCollegeofMedViews:212 1ratingsTime:02:59More inScience Technology

Follow this link:
Science Talk: Myelodysplastic Syndromes (MDS) Linked to Abnormal Stem Cells - Video

Recommendation and review posted by Bethany Smith

Coast To Coast AM - 2011-11-15 - Regenerative Medicine / Dulce Base (Full Show)
Date: 11-15-11 Host: George Noory Guests: Anthony F. Sanchez, Christian Wilde In the first half, researcher Christian Wilde talked about the emerging field of regenerative medicine, and how scientists are actually building replacement body parts with stem cells. He announced that Dr. Richard Burt at Northwestern University #39;s School of Medicine has been successfully using patients own bone marrow stem cells to treat a variety of autoimmune diseases like Lupus, and Type 1 Diabetes. It may be possible to expand human lifespan up to around 150 years, Wilde declared, now that replacement organs such as kidneys and livers can be grown in a matter of 6-8 weeks. He cited an instance where new stem cells were injected into the cadaver heart of a rat, and in a few days it started beating again. And, he added, at the Univ. of Pittsburgh, a Marine who lost his right hand, has had a successful transplant of a cadaver hand. Wilde also spoke about heart health, and the importance of taking homocysteine and CRP (C-Reactive Protein) tests in order to monitor cardiac issues and inflammation. Supplements such as turmeric can reduce inflammation and protect against some cancers, he noted. -------------------------- In the latter half, software engineer and UFO researcher, Anthony F. Sanchez, presented details about an underground base in Dulce, New Mexico, and its connection to the Greys. Much of his information comes from "Colonel X," a retired military whistleblower, who wishes to remain ...From:PIGAMOUSViews:267 5ratingsTime:02:33:31More inNonprofits Activism

See the article here:
Coast To Coast AM - 2011-11-15 - Regenerative Medicine / Dulce Base (Full Show) - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more!
Bone marrow stem cells helped Emery M. after having pain in his foot and other minor problems. He came to Dr. David Steenblock for adult stem cell treatments and did wonderfully. To find out more about bone marrow stem cells and how legal stem cells are done here in the US call Dr. Steenblock #39;s office: 1-800-300-1063.From:STEMCELLinfoViews:37 0ratingsTime:02:00More inScience Technology

Read the rest here:
Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more! - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair
xxsurl.com Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair Ventricular Remodeling in Ischemic Cardiomyopathy.- Myocardial Regeneration: Which Cell and Why.- Cardiac Stem Cells for Myocardial Regeneration.- A Historic Recapitulation of Myoblast Transplantation.- Myoblast Cell Transplantation Preclinical Studies.- Skeletal Myoblasts: The European Experience.- Skeletal Myoblasts: The US Experience.- Progenitor Cells for Cardiac Regeneration.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Preclinical Experience.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Clinical Experience, Surgical Delivery.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The German Experience.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The Spanish Experience.- Mobilizing Bone Marrow Stem Cells for Myocardial Repair after Acute Myocardial Infarction.- Percutaneous Myoblast Transplantation: Steps in Translational Research.- A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation.- Tissue Engineering for Myocardial Regeneration.- The Role of PET Scan in Stem Cell Therapy.- The Measurement of Systolic Function in the Mammalian Heart.- Electrophysiological Aspects of Cell Transplantation.- Regulatory Considerations in Manufacturing, Product Testing, and Preclinical Development of Cellular Products for Cardiac Repair.- Appendix: Catheter Descriptions.- Index. EAN ...From:maurinecooper3Views:56 0ratingsTime:00:12More inPeople Blogs

Go here to see the original:
Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair - Video

Recommendation and review posted by Bethany Smith

Stem cells for critical limb ischemia (NAPLES Study).m4v
This is the procedure of intra arterial autologous transplant of bone marrow stem cells for the treatment of critical limb ischemia according to NAPLES Study.From:Alessandro SchiavettaViews:47 0ratingsTime:01:16More inScience Technology

More here:
Stem cells for critical limb ischemia (NAPLES Study).m4v - Video

Recommendation and review posted by Bethany Smith